Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The evolving landscape of antibody-drug conjugates in gynecologic cancers
Anthony W. Tolcher, Erika Hamilton, Robert L. Coleman
Cancer Treatment Reviews (2023) Vol. 116, pp. 102546-102546
Closed Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

Clinical and translational advances in ovarian cancer therapy
Panagiotis A. Konstantinopoulos, Ursula A. Matulonis
Nature Cancer (2023) Vol. 4, Iss. 9, pp. 1239-1257
Closed Access | Times Cited: 116
Drug resistance in ovarian cancer: from mechanism to clinical trial
Ling Wang, Xin Wang, Xueping Zhu, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 44
Different Targeting Ligands-Mediated Drug Delivery Systems for Tumor Therapy
Shuxin Yan, Jintong Na, Xiyu Liu, et al.
Pharmaceutics (2024) Vol. 16, Iss. 2, pp. 248-248
Open Access | Times Cited: 31
The emerging roles of long non-coding RNA (lncRNA) H19 in gynecologic cancers
Majid Ghasemian, Mojtaba Zehtabi, Mahrokh Abouali Gale Dari, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 8
Sulfur-containing peptides: Synthesis and application in the discovery of potential drug candidates
Yanyan Liao, Ming Wang, Xuefeng Jiang
Current Opinion in Chemical Biology (2023) Vol. 75, pp. 102336-102336
Closed Access | Times Cited: 13
Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer
Weisong Li, Kai Zhang, Wenjun Wang, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 5
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005
Jung‐Min Lee, Mark F. Brady, Austin Miller, et al.
Journal of Clinical Oncology (2024)
Closed Access | Times Cited: 5
Key considerations based on pharmacokinetic/pharmacodynamic in the design of antibody-drug conjugates
Yangyang Gao, Yuwei Xia, Yixin Chen, et al.
Frontiers in Oncology (2025) Vol. 14
Open Access
The Icarian flight of antibody-drug conjugates: target selection amidst complexity and tackling adverse impacts
Han Liu, Hongye Zeng, Xiaojing Qin, et al.
Protein & Cell (2025)
Open Access
Evaluating the safety of antibody-drug conjugates in lung cancer: A systematic review and meta-analysis
He Qi, Lin Jiang, Yan Xu, et al.
Lung Cancer (2025) Vol. 201, pp. 108425-108425
Closed Access
Second-line antibody-drug conjugates for the treatment of metastatic human papillomavirus-independent gastric-type adenocarcinoma of cervix: The Singapore experience
Daniel Jia Ming Ang, Ke Xin Bok, Shing Lih Wong, et al.
Gynecologic Oncology Reports (2025) Vol. 58, pp. 101709-101709
Open Access
Clinical applications of antibody drug conjugates for gynecologic malignancies: Review of available medicines and emerging therapeutics
Alyssa Bujnak, Samantha Solaru, Krishnansu S. Tewari
Gynecologic Oncology (2025) Vol. 195, pp. 180-191
Open Access
Advances in the use of nanoparticles for specific cell-target delivery of anti-cancer agents
Ana Belén Diaz-Ruano, Eliana Gomez-Jimenez, Gloria Llamas-Jimenez, et al.
Life Sciences (2025) Vol. 371, pp. 123604-123604
Closed Access
The ever-expanding landscape of antibody-drug conjugates (ADCs) in solid tumors: A systematic review
Panagiotis Filis, Ioannis Zerdes, Theodora Soumala, et al.
Critical Reviews in Oncology/Hematology (2023) Vol. 192, pp. 104189-104189
Open Access | Times Cited: 8
Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors
Blair McNamara, Michelle Greenman, Nicole Pebley, et al.
Molecules (2023) Vol. 28, Iss. 21, pp. 7389-7389
Open Access | Times Cited: 7
Antibody–Drug Conjugates: Advancing from Magic Bullet to Biological Missile
Ana Veneziani, Suku Sneha, Amit M. Oza
Clinical Cancer Research (2024) Vol. 30, Iss. 8, pp. 1434-1437
Open Access | Times Cited: 2
The Efficacy and Safety of Folate Receptor α‐Targeted Antibody‐Drug Conjugate Therapy in Patients With High‐Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers: A Systematic Review and Meta‐Analysis
Eun Taeg Kim, Ji Hyun Kim, Eun Young Park, et al.
Cancer Medicine (2024) Vol. 13, Iss. 21
Open Access | Times Cited: 2
Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer
Rebecca L. Porter, Ursula A. Matulonis
Expert Review of Anticancer Therapy (2023) Vol. 23, Iss. 8, pp. 783-796
Closed Access | Times Cited: 6
Exploring the Sensitivity of Antibody–Drug Conjugate Efficacy to the Selection of Payload, Antibody, and Cell line
M.B. Rao, Shruthi Murali, Danielle Amores, et al.
Bioconjugate Chemistry (2024)
Closed Access | Times Cited: 1
Sacituzumab govitecan in heavily pretreated, platinum-resistant high grade serous ovarian cancer
Michelle Greenman, Stefania Bellone, Cem Demirkiran, et al.
Gynecologic Oncology Reports (2024) Vol. 54, pp. 101459-101459
Closed Access | Times Cited: 1
The role of B7-H4 in ovarian cancer immunotherapy: current status, challenges, and perspectives
Lu Zhou, Yuanqiong Duan, Kaiyu Fu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
METTL3 facilitates the progression of cervical cancer by m6A modification-mediated up-regulation of NEK2
Yilin Guo, Yangyang Bai, Lu Wang, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Navigating the Future: Advancements in Monoclonal Antibody Nanoparticle Therapy for Cancer
Harshad S. Kapare, Mayuri Bhosale, Ritesh Bhole
Journal of Drug Delivery Science and Technology (2024) Vol. 104, pp. 106495-106495
Closed Access | Times Cited: 1
Mirvetuximab soravtansine in folate receptor alpha-positive, platinum-resistant ovarian cancers: a profile of its use
Simon Fung, Yahiya Y. Syed
Drugs & Therapy Perspectives (2024) Vol. 40, Iss. 2, pp. 53-60
Closed Access
Neuerungen in der Systemtherapie des metastasierten Zervixkarzinoms*
Verena Friebe, Anne Kathrin Volkmer, Tanja Fehm, et al.
InFo Hämatologie + Onkologie (2024) Vol. 27, Iss. 3, pp. 14-20
Closed Access
Page 1 - Next Page

Scroll to top